TY  - JOUR
T1  - The Role of Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) in Biomarkers of Diabetic Nephropathy
TT  - The Role of Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) in Biomarkers of Diabetic Nephropathy
AU  - Tur, Kağan
AU  - Güçlü, Kenan
PY  - 2025
DA  - May
Y2  - 2025
DO  - 10.30934/kusbed.1653929
JF  - Kocaeli Üniversitesi Sağlık Bilimleri Dergisi
JO  - KOU Sag Bil Derg
PB  - Kocaeli Üniversitesi
WT  - DergiPark
SN  - 2149-8571
SP  - 65
EP  - 69
VL  - 11
IS  - 2
LA  - en
AB  - Objective: This study investigates the potential role of Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) as a novel biomarker, evaluating its associations with established urinary biomarkers and glycemic control indicators in diabetes mellitus and diabetic nephropathy (DN).Methods: A cross-sectional study was conducted involving 84 participants stratified by albuminuria levels into normoalbuminuria, microalbuminuria, and macroalbuminuria groups. MANF levels were quantified using enzyme-linked immunosorbent assays (ELISA), while urinary biomarkers and HbA1C were measured using standard clinical methods. Correlation analyses and multivariate regression models were employed to assess relationships between MANF and biomarkers.Results: MANF levels demonstrated a significant upward trend across albuminuria categories, with the highest levels observed in the macroalbuminuria group (514.5±112.3 pg/mL, p
KW  - Kidney Diseases
KW  - Chronic
KW  - Diabetic Nephropaties
KW  - Biological Markers
KW  - Blood Glucose
KW  - Neurotrophic Factors
N2  - Objective: This study investigates the potential role of Mesencephalic Astrocyte-Derived Neurotrophic Factor (MANF) as a novel biomarker, evaluating its associations with established urinary biomarkers and glycemic control indicators in diabetes mellitus and diabetic nephropathy (DN).Methods: A cross-sectional study was conducted involving 84 participants stratified by albuminuria levels into normoalbuminuria, microalbuminuria, and macroalbuminuria groups. MANF levels were quantified using enzyme-linked immunosorbent assays (ELISA), while urinary biomarkers and HbA1C were measured using standard clinical methods. Correlation analyses and multivariate regression models were employed to assess relationships between MANF and biomarkers.Results: MANF levels demonstrated a significant upward trend across albuminuria categories, with the highest levels observed in the macroalbuminuria group (514.5±112.3 pg/mL, p
CR  - Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, Hoy WE. Biomarkers in chronic kidney disease: a review. Kidney Int. 2011;80(8):806-821. doi:10.1038/ki.2011.198
CR  - Zhao YY. Metabolomics in chronic kidney disease. Clin Chim Acta. 2013;422:59-69. doi:10.1016/j.cca.2013.03.033
CR  - Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? Clin Chim Acta. 2015;438:350-357. doi:10.1016/j.cca.2014.08.039
CR  - Julkunen H. Metabolic blood biomarker profiling for chronic kidney disease prediction. Nephrol Dial Transplant. 2023;38. doi:10.1093/ndt/gfad063c_5650
CR  - Tesch GH. Review: Serum and urine biomarkers of kidney disease: a pathophysiological perspective. Nephrology (Carlton). 2010;15(6):609-616. doi:10.1111/j.1440- 1797.2010.01361.x
CR  - Zhang ZH, Chen H, Vaziri ND, et al. Metabolomic signatures of chronic kidney disease of diverse etiologies in the rats and humans. J Proteome Res. 2016;15(10):3802-3812. doi:10.1021/acs.jproteome.6b00583
CR  - Breit M, Weinberger KM. Metabolic biomarkers for chronic kidney disease. Arch Biochem Biophys. 2016;589:62-80. doi:10.1016/j.abb.2015.07.018
CR  - Kim Y, Lee H, Manson SR, et al. Mesencephalic astrocytederived neurotrophic factor as a urine biomarker for endoplasmic reticulum stress-related kidney diseases. J Am Soc Nephrol. 2016;27(10):2974-2982. doi:10.1681/ASN.2014100986
CR  - Liu H, Tang X, Gong L. Mesencephalic astrocyte-derived neurotrophic factor and cerebral dopamine neurotrophic factor: new endoplasmic reticulum stress response proteins. Eur J Pharmacol. 2015;750:118-122. doi:10.1016/j.ejphar.2015.01.016
CR  - Lindahl M, Danilova T, Palm E, et al. MANF is indispensable for the proliferation and survival of pancreatic β cells. Cell Rep. 2014;7(2):366-375. doi:10.1016/j.celrep.2014.03.023
CR  - Kim WJ, Park CY, Lee KB, et al. Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction. Diabetes Care. 2012;35(2):281-286. doi:10.2337/dc11-1462
CR  - Zhang H, Zuo JJ, Dong SS, et al. Identification of potential serum metabolic biomarkers of diabetic kidney disease: a widely targeted metabolomics study. J Diabetes Res. 2020;2020:3049098. doi:10.1155/2020/3049098
CR  - Inaba M, Okuno S, Kumeda Y, et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol. 2007;18(3):896- 903. doi:10.1681/ASN.2006070772
CR  - Dozio E, Corradi V, Proglio M, et al. Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKDG5D). Diabetes Res Clin Pract. 2018;140:9-17. doi:10.1016/j.diabres.2018.03.017
CR  - Looker HC, Colombo M, Hess S, et al. Biomarkers of rapid chronic kidney disease progression in type 2 diabetes. Kidney Int. 2015;88(4):888-896. doi:10.1038/ki.2015.199
CR  - Zelnick LR, Batacchi ZO, Ahmad I, et al. Continuous glucose monitoring and use of alternative markers to assess glycemia in chronic kidney disease. Diabetes Care. 2020;43(10):2379- 2387. doi:10.2337/dc20-0915
CR  - Mizdrak M, Kumrić M, Kurir TT, Božić J. Emerging biomarkers for early detection of chronic kidney disease. J Pers Med. 2022;12(4):548. doi:10.3390/jpm12040548
CR  - Speeckaert M, Van Biesen W, Delanghe J, et al. Are there better alternatives than haemoglobin A1c to estimate glycaemic control in the chronic kidney disease population? Nephrol Dial Transplant. 2014;29(12):2167-2177. doi:10.1093/ndt/gfu006
CR  - Chaudhary K, Phadke G, Nistala R, Weidmeyer CE, McFarlane SI, Whaley-Connell A. The emerging role of biomarkers in diabetic and hypertensive chronic kidney disease. Curr Diab Rep. 2010;10(1):37-42. doi:10.1007/s11892-009-0080-z
CR  - Lousa I, Reis F, Beirão I, Alves R, Belo L, Santos-Silva A. New potential biomarkers for chronic kidney disease management— a review of the literature. Int J Mol Sci. 2020;22(1):43. doi:10.3390/ijms22010043
CR  - Galindo RJ, Beck RW, Scioscia MF, Umpierrez GE, Tuttle KR. Glycemic monitoring and management in advanced chronic kidney disease. Endocr Rev. 2020;41(5):756-774. doi:10.1210/endrev/bnaa017
CR  - Cardenas-Gonzalez M, Srivastava A, Pavkovic M, et al. Identification, confirmation, and replication of novel urinary microRNA biomarkers in lupus nephritis and diabetic nephropathy. Clin Chem. 2017;63(9):1515-1526. doi:10.1373/clinchem.2017.274175
CR  - Lecamwasam A, Ekinci EI, Saffery R, Dwyer KM. Potential for novel biomarkers in diabetes-associated chronic kidney disease: epigenome, metabolome, and gut microbiome. Biomedicines. 2020;8(9):341. doi:10.3390/biomedicines8090341
UR  - https://doi.org/10.30934/kusbed.1653929
L1  - https://dergipark.org.tr/tr/download/article-file/4673135
ER  -